Sanofi defeats Novo Nordisk in Danish high court

A press release from Novo Nordisk, comparing Novo's Tresiba to French Sanofi's insulins, was misleading, against the Medicines Act and a violation of good marketing practice. This is the judgment of the Danish Maritime and Commercial High Court.

Photo: /Ritzau Scanpix/Linda Kastrup

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles